[go: up one dir, main page]

CL2014003283A1 - Formulación farmacéutica. - Google Patents

Formulación farmacéutica.

Info

Publication number
CL2014003283A1
CL2014003283A1 CL2014003283A CL2014003283A CL2014003283A1 CL 2014003283 A1 CL2014003283 A1 CL 2014003283A1 CL 2014003283 A CL2014003283 A CL 2014003283A CL 2014003283 A CL2014003283 A CL 2014003283A CL 2014003283 A1 CL2014003283 A1 CL 2014003283A1
Authority
CL
Chile
Prior art keywords
pharmaceutical formulation
formulation
pharmaceutical
Prior art date
Application number
CL2014003283A
Other languages
English (en)
Inventor
Andrew Jeffrey Yates
James Gregory Clipstone
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48745904&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2014003283(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Publication of CL2014003283A1 publication Critical patent/CL2014003283A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Inorganic Chemistry (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
CL2014003283A 2012-06-21 2014-11-28 Formulación farmacéutica. CL2014003283A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261662621P 2012-06-21 2012-06-21

Publications (1)

Publication Number Publication Date
CL2014003283A1 true CL2014003283A1 (es) 2016-04-01

Family

ID=48745904

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2014003283A CL2014003283A1 (es) 2012-06-21 2014-11-28 Formulación farmacéutica.

Country Status (25)

Country Link
US (1) US20150150979A1 (es)
EP (1) EP2864356A1 (es)
JP (1) JP6157611B2 (es)
KR (1) KR20150032941A (es)
CN (1) CN104520326A (es)
AR (1) AR091530A1 (es)
AU (1) AU2013279347A1 (es)
BR (1) BR112014031841A2 (es)
CA (1) CA2876012A1 (es)
CL (1) CL2014003283A1 (es)
CO (1) CO7170174A2 (es)
EA (1) EA201590061A1 (es)
EC (1) ECSP15002095A (es)
HK (1) HK1205146A1 (es)
IL (1) IL235921A0 (es)
MA (1) MA37777B1 (es)
MX (1) MX2014014717A (es)
NZ (1) NZ702342A (es)
PE (1) PE20150190A1 (es)
PH (1) PH12014502596A1 (es)
SG (1) SG11201407779YA (es)
TN (1) TN2014000498A1 (es)
TW (1) TW201406398A (es)
WO (1) WO2013190047A1 (es)
ZA (1) ZA201409020B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
SG10201902915VA (en) 2014-10-01 2019-04-29 Eagle Biologics Inc Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
US11738036B2 (en) 2016-05-28 2023-08-29 Rajiv Gandhi Centre For Biotechnology, An Autonomous Institute Under The Department Of Biotechnology, Government Of India Uttroside B and derivatives thereof as therapeutics for hepatocellular carcinoma
JP2019536761A (ja) * 2016-10-31 2019-12-19 フレゼニウス カービ ドイチュラント ゲーエムベーハー 液体医薬組成物
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
CA3049857A1 (en) 2017-01-11 2018-07-19 Celltrion Inc. Stable liquid formulation
WO2018211517A1 (en) 2017-05-16 2018-11-22 Bhami's Research Laboratory, Pvt. Ltd. High concentration protein formulations with reduced viscosity
GB201719447D0 (en) * 2017-11-23 2018-01-10 Ucb Biopharma Sprl Pharmaceutical composition
US20230405018A1 (en) * 2020-11-18 2023-12-21 Bexson Biomedical, Inc. Flumazenil formulations for subcutaneous injection and methods of treatment using gaba receptor modulators
EP4247340A4 (en) 2020-11-18 2024-10-02 Bexson Biomedical, Inc. COMPLEXING SALT FORMULATIONS OF PHARMACEUTICAL COMPOUNDS

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1324776E (pt) * 2000-10-12 2009-12-23 Genentech Inc Formulações de proteína concentradas de viscosidade reduzida
GB0113179D0 (en) * 2001-05-31 2001-07-25 Novartis Ag Organic compounds
EP3178492A1 (en) * 2003-04-04 2017-06-14 Genentech, Inc. High concentration antibody and protein formulations
EP1865986B1 (en) * 2005-03-08 2016-02-17 Pfizer Products Inc. Anti-ctla-4 antibody compositions
PE20081610A1 (es) * 2007-01-09 2008-12-09 Wyeth Corp Formulaciones de anticuerpos anti-il-13 y usos de los mismos
EP2170390B1 (en) * 2007-06-14 2018-11-07 Biogen MA Inc. Natalizumab antibody formulations
KR20130060227A (ko) * 2010-05-03 2013-06-07 제넨테크, 인크. 단백질-함유 제제의 점도 감소에 유용한 조성물 및 방법
SMT202000095T1 (it) * 2010-05-14 2020-03-13 Amgen Inc Formulazioni di anticorpi anti-sclerostina ad alta concentrazione
EP2588141A4 (en) * 2010-07-02 2014-12-03 Medimmune Llc ANTIBODY FORMULATIONS
WO2012141978A2 (en) * 2011-04-07 2012-10-18 Glaxosmithkline Llc Formulations with reduced viscosity
WO2012151199A1 (en) * 2011-05-02 2012-11-08 Immunomedics, Inc. Ultrafiltration concentration of allotype selected antibodies for small-volume administration

Also Published As

Publication number Publication date
SG11201407779YA (en) 2015-02-27
PH12014502596A1 (en) 2015-01-12
MX2014014717A (es) 2015-03-06
MA37777B1 (fr) 2017-07-31
CA2876012A1 (en) 2013-12-27
US20150150979A1 (en) 2015-06-04
JP2015520206A (ja) 2015-07-16
WO2013190047A1 (en) 2013-12-27
IL235921A0 (en) 2015-01-29
EA201590061A1 (ru) 2015-05-29
NZ702342A (en) 2016-07-29
TN2014000498A1 (en) 2016-03-30
PE20150190A1 (es) 2015-02-13
AU2013279347A1 (en) 2014-12-18
MA20150436A1 (fr) 2015-11-30
CN104520326A (zh) 2015-04-15
AR091530A1 (es) 2015-02-11
ECSP15002095A (es) 2015-11-30
KR20150032941A (ko) 2015-03-31
BR112014031841A2 (pt) 2017-06-27
ZA201409020B (en) 2016-09-28
HK1205146A1 (en) 2015-12-11
TW201406398A (zh) 2014-02-16
CO7170174A2 (es) 2015-01-28
JP6157611B2 (ja) 2017-07-05
EP2864356A1 (en) 2015-04-29

Similar Documents

Publication Publication Date Title
DK3181128T3 (da) Farmaceutisk nilotinib-sammensætning
BR112014028602A2 (pt) formulação líquida.
DK3030262T3 (da) Kombineret farmaceutisk sammensætning
SI3725778T1 (sl) Formulacije enzalutamida
BR112015002738A2 (pt) composto , e , composição farmacêutica
DK2858671T3 (da) Antistofformulering
DK2890397T3 (da) Antiprolactinreceptor-antistofformulering
PT2854768T (pt) Composições farmacêuticas de pemetrexed
BR112015003259A2 (pt) composto, composição farmacêutica, e, composição de vacina.
DK2900645T3 (da) Herbicidt aktive 3-phenylisoxazolinderivater
CL2014003283A1 (es) Formulación farmacéutica.
CO6940426A2 (es) Formulaciones farmacéuticas
DK2897594T3 (da) Farmaceutisk sammensætning
DK2868318T4 (da) Injicerbar formulering
EP2838488A4 (en) DRUGS DONORS
EP2883547A4 (en) MEDICINE
FR2986872B1 (fr) .
DK2854765T3 (da) Farmaceutisk pemetrexed-opløsning
BR112014032501A2 (pt) composto, e, composição farmacêutica.
BR112014028443A2 (pt) composição estéril.
CO7091176A2 (es) Diagnóstico farmacéutico
DK3473255T3 (da) Farmaceutisk formulering omfattende ciclesonid
DK3003401T3 (da) Farmaceutisk præparat
DK3427723T3 (da) Rna-formulering til immunterapi
BR112014027645A2 (pt) 5-halogenopirazol bifenilcarboxamidas.